原发性中枢神经系统淋巴瘤患者血清miR-548b、miR-21的表达及其对预后的预测价值-东南大学学报医学版

原发性中枢神经系统淋巴瘤患者血清miR-548b、miR-21的表达及其对预后的预测价值

单位：湖北文理学院附属谷城医院神经外科, 湖北襄阳 441700

关键词：原发性中枢神经系统淋巴瘤微小核糖核酸-548b 微小核糖核酸-21 预后生存率

分类号：R739.41

出版年·卷·期（页码）：2022·41·第二期（221-226）

摘要：

目的:探讨原发性中枢神经系统淋巴瘤(PCNSL)患者血清微小核糖核酸(miR)-548b、miR-21表达情况,分析其对预后的预测价值。方法:选择我院2013年5月至2019年5月收治的PCNSL患者84例为PCNSL组,同期于我院进行体检的65例健康志愿者为对照组。比较两组研究对象血清miR-548b、miR-21表达水平,分析二者与病理特征的关系。随访36个月,分析不同miR-548b、miR-21表达患者的预后,绘制受试者工作特征(ROC)曲线,分析二者评估预后的曲线下面积(AUC)。结果:PCNSL组血清miR-548b表达水平低于对照组,miR-21表达水平高于对照组(均P＜0.05)。miR-548b低表达组、miR-21高表达组肿瘤数目≥2个、肿瘤大小≥3 cm、深部病变占比均高于miR-548b高表达组、miR-21低表达组(均P＜0.05)。miR-548b高表达组、miR-21低表达组患者的3年累积生存率分别高于miR-548b低表达组、miR-21高表达组(均P＜0.05)。血清miR-548b、miR-21表达单独及联合评估预后的AUC分别为0.734、0.779及0.810。结论:PCNSL患者血清miR-548b表达水平降低,miR-21表达水平增高,miR-548b低表达与miR-21过表达均会影响PCNSL的预后。

Objective: To evaluate the expression of microRNA(miR)-548b and miR-21 in patients with primary central nervous system lymphoma(PCNSL), and to analyze its prognostic value. Methods: Between May 2013 and May 2019,a total of 84 PCNSL patients admitted to our hospital were included in PCNSL group, and 65 healthy volunteers undergoing physical examination in our hospital during the same period were selected as control group. The expression levels of serum miR-548b and miR-21 were compared between the two groups, and the relationship between the miR-548b and miR-21 and the pathological features was analyzed. The PCNSL patients were followed up for 36 months. The tumor-free and cumulative survival of patients with different miR-548b and miR-21 expressions were analyzed by log-rank χ² test, and the receiver operating characteristic(ROC) curve was drawn to analyze the area under the curve(AUC) between the two to assess the prognosis. Results: The expression of serum miR-548b in the PCNSL group was lower than that of the control group, and the expression of miR-21 was higher than that of the control group(all P＜0.05). The proportion of the number of tumors was≥2, the diameter of tumor was ≥3 cm, and deep lesions in miR-548b low expression group and miR-21 high expression group were higher than those in miR-548b high expression group and miR-21 low expression group respectively(all P＜0.05) .The 3-year cumulative survival rates of miR-548b high expression group and miR-21 low expression group were higher than those of miR-548b low expression group and miR-21 high expression group, respectively(all P＜0.05). The AUC of serum miR-548b and miR-21 expression alone and the combination of the two to assess prognosis was 0.734, 0.779, 0.810, respectively. Conclusion: Serum miR-548b expression level decreases and miR-21 expression level increases in patients with PCNSL. Low expression of miR-548b and overexpression of miR-21 will affect the prognosis of patients.

参考文献：

[1] SINICROPE K,BATCHELOR T.Primary central nervous system lymphoma[J].Neurol Clin,2018,36(3):517-532.
[2] VELASCO R,MERCADAL S,VIDAL N,et al.Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain:a multicentric study[J].J Neuro Oncol,2020,148(5):545-554.
[3] SHIN D W,KIM J H,KIM Y H,et al.Primary central nervous system lymphoma involving the hypothalamic pituitary axis:a case series and pooled analysis[J].J Neuro Oncol,2020,147(4):339-349.
[4] 陈亚凤,毕中秋,翟晓菲,等.中枢神经系统弥漫大B细胞淋巴瘤相关microRNAs的研究进展[J].现代生物医学进展,2016,16(2):390-392,396.
[5] 熊艳,刘沛武,万兵.miR-548b靶向肿瘤转移相关蛋白-2抑制恶性胶质瘤增殖和侵袭的研究[J].中国临床药理学杂志,2020,36(3):305-308.
[6] 李丽,杨一飞,杨俊超,等.miR-155,miR-21在黏膜相关淋巴样组织结外边缘区淋巴瘤组织和细胞中的表达及意义[J].临床血液学杂志,2018,31(3):201-204.
[7] HAN C H,BATCHELOR T T.Diagnosis and management of primary central nervous system lymphoma[J].Cancer,2017,123(22):4314-4324.
[8] ENBLAD G,MARTINSSON G,BAECKLUND E,et al.Population-based experience on primary central nervous system lymphoma 2000-2012:the incidence is increasing[J].Acta Oncol,2017,56(4):599-607.
[9] 李璐,董晓强,李艳艳,等.MicroRNA与弥漫大B淋巴瘤预后关系的系统综述和Meta分析[J].中华疾病控制杂志,2018,22(5):510-517.
[10] WANG Z L,WU X F,HOU X W,et al.miR-548b-3p functions as a tumor suppressor in lung cancer[J].Laser Med Sci,2020,35(4):833-839.
[11] 曹慧琴,韦玮.淋巴瘤患者血浆中miR-21、miR-155、miR-210的表达及临床意义[J].中国实验诊断学,2016,20(5):764-767.
[12] BERANIA I,CARDIN G B,CLEMENT I,et al.Four PTEN-targeting co-expressed miRNAs and ACTN4-targeting miR-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue[J].Int J Cancer,2017,141(11):2318-2328.
[13] TAKASHIMA Y,KAWAGUCHI A,IWADATE Y,et al.miR-101,miR-548b,miR-554,and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma[J].PLoS One,2020,15(2):e0229577.
[14] 冯晓云,严玲玲.miR-21,miR-155,miR-210的临床表达意义及其与淋巴瘤病理特征的相关性分析[J].中国医药导报,2017,14(23):84-87.
[15] PAN Y,LIANG W,ZHAO X,et al.miR-548b inhibits the proliferation and invasion of malignant gliomas by targeting metastasis tumor-associated protein-2[J].Neuroreport,2016,27(17):1266-1273.
[16] SONG J,SHAO Q,LI C,et al.Effects of microRNA-21 on apoptosis by regulating the expression of PTEN in diffuse large B-cell lymphoma[J].Medicine,2017,96(39):e7952.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录